An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2025-01-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000003343 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841550806716776448 |
|---|---|
| author | Bin Xue Yifan Liu Min Zhang Gangfeng Xiao Xiu Luo Lili Zhou Shiguang Ye Yan Lu Wenbin Qian Li Wang Ping Li Aibin Liang Sihan Zhou Xiuyuan Hao |
| author_facet | Bin Xue Yifan Liu Min Zhang Gangfeng Xiao Xiu Luo Lili Zhou Shiguang Ye Yan Lu Wenbin Qian Li Wang Ping Li Aibin Liang Sihan Zhou Xiuyuan Hao |
| author_sort | Bin Xue |
| collection | DOAJ |
| format | Article |
| id | doaj-art-e4cd6f9c9d2248fc95f5332bebe73c53 |
| institution | Kabale University |
| issn | 0366-6999 2542-5641 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj-art-e4cd6f9c9d2248fc95f5332bebe73c532025-01-10T01:10:37ZengWolters KluwerChinese Medical Journal0366-69992542-56412025-01-01138110811010.1097/CM9.0000000000003343202501050-00015An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma riskBin Xue0Yifan Liu1Min Zhang2Gangfeng Xiao3Xiu Luo4Lili Zhou5Shiguang Ye6Yan Lu7Wenbin Qian8Li Wang9Ping Li10Aibin Liang11Sihan ZhouXiuyuan Hao1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China3 Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China4 Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China1 Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, Chinahttp://journals.lww.com/10.1097/CM9.0000000000003343 |
| spellingShingle | Bin Xue Yifan Liu Min Zhang Gangfeng Xiao Xiu Luo Lili Zhou Shiguang Ye Yan Lu Wenbin Qian Li Wang Ping Li Aibin Liang Sihan Zhou Xiuyuan Hao An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk Chinese Medical Journal |
| title | An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk |
| title_full | An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk |
| title_fullStr | An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk |
| title_full_unstemmed | An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk |
| title_short | An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk |
| title_sort | assessment model for efficacy of autologous cd19 chimeric antigen receptor t cell therapy and relapse or refractory diffuse large b cell lymphoma risk |
| url | http://journals.lww.com/10.1097/CM9.0000000000003343 |
| work_keys_str_mv | AT binxue anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT yifanliu anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT minzhang anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT gangfengxiao anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT xiuluo anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT lilizhou anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT shiguangye anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT yanlu anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT wenbinqian anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT liwang anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT pingli anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT aibinliang anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT sihanzhou anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT xiuyuanhao anassessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT binxue assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT yifanliu assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT minzhang assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT gangfengxiao assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT xiuluo assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT lilizhou assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT shiguangye assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT yanlu assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT wenbinqian assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT liwang assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT pingli assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT aibinliang assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT sihanzhou assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk AT xiuyuanhao assessmentmodelforefficacyofautologouscd19chimericantigenreceptortcelltherapyandrelapseorrefractorydiffuselargebcelllymphomarisk |